Xilio Therapeutics, Inc.

Xilio Therapeutics, Inc., a clinical-stage biotech firm, reported total revenue of $43.8 million for FY 2025, a significant increase from $6.3 million in FY 2024, driven by collaboration and license revenue from agreements with AbbVie ($20.1 million) and Gilead ($23.6 million), including milestones. This marked a YoY revenue growth of approximately 591%. Operating expenses rose to $85.7 million from $66.9 million, reflecting higher R&D ($56.0 million vs $41.2 million) due to clinical advancements in vilastobart, efarindodekin alfa, and XTX501, and G&A ($29.7 million vs $24.8 million). Loss from operations narrowed to -$42.0 million from -$60.6 million. Net loss improved to -$35.0 million from -$58.2 million, aided by a $5.8 million gain from changes in common stock warrant liabilities and $1.1 million other income. Basic and diluted EPS was -$4.00 per share on 8.4 million weighted average shares. Balance sheet strengthened with cash and equivalents at $137.5 million (up from $55.3 million), total assets $154.7 million, and stockholders' equity $35.3 million. Net cash used in operations was -$5.0 million vs -$18.4 million YoY, with financing providing $87.8 million mainly from warrant offerings. Management states cash sufficient through end-2027, excluding milestones, supporting pipeline advancement without near-term dilution needs.

Key Takeaways